These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 23182252)

  • 1. [Surgical prognostic factors of gastroenteropancreatic neuroendocrine tumors (GEP NET)].
    Medrano-Guzmán R; Alvarado-Cabrero I; González-Rodríguez D; López-García SC; Páez-Agraz F
    Rev Med Inst Mex Seguro Soc; 2012; 50(3):243-8. PubMed ID: 23182252
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Resectability of primary gastroenteropancreatic neuroendocrine tumor as a prognostic factor for survival.
    Medrano-Guzmán R; López-García SC; Torres-Vargas S; González-Rodríguez D; Alvarado-Cabrero I
    Cir Cir; 2011; 79(6):498-504. PubMed ID: 22169366
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Survival prognostic factors of gastro-enteric-pancreatic neuroendocrine tumors after primary tumor resection in a single tertiary center: Comparison of gastro-enteric and pancreatic locations.
    Russolillo N; Vigano' L; Razzore P; Langella S; Motta M; Bertuzzo F; Papotti M; Ferrero A
    Eur J Surg Oncol; 2015 Jun; 41(6):751-7. PubMed ID: 25887286
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictors of long-term outcome in patients with well-differentiated gastroenteropancreatic neuroendocrine tumors after peptide receptor radionuclide therapy with 177Lu-octreotate.
    Ezziddin S; Attassi M; Yong-Hing CJ; Ahmadzadehfar H; Willinek W; Grünwald F; Guhlke S; Biersack HJ; Sabet A
    J Nucl Med; 2014 Feb; 55(2):183-90. PubMed ID: 24434296
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Clinicopathological features and multivariate analysis of prognostic factors for patients with gastroenteropancreatic neuroendocrine tumors].
    Wang X; Song ZF; Yao WX; Pan CC; Xiang MF; Wang H
    Zhonghua Yi Xue Za Zhi; 2013 May; 93(18):1411-4. PubMed ID: 24025507
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Neuroendocrine tumors of the gastroenteropancreatic system--reevaluation using the Capella classification].
    Brüwer M; Pahlov-Nejad T; Herbst H; Senninger N; Schürmann G
    Zentralbl Chir; 2003 Aug; 128(8):656-62. PubMed ID: 12931261
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic factors influencing survival from metastatic (stage IV) gastroenteropancreatic well-differentiated endocrine carcinoma.
    Durante C; Boukheris H; Dromain C; Duvillard P; Leboulleux S; Elias D; de Baere T; Malka D; Lumbroso J; Guigay J; Schlumberger M; Ducreux M; Baudin E
    Endocr Relat Cancer; 2009 Jun; 16(2):585-97. PubMed ID: 19240182
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Morbidity and mortality of aggressive resection in patients with advanced neuroendocrine tumors.
    Norton JA; Kivlen M; Li M; Schneider D; Chuter T; Jensen RT
    Arch Surg; 2003 Aug; 138(8):859-66. PubMed ID: 12912744
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Localized high-grade gastroenteropancreatic neuroendocrine tumors: Defining prognostic and therapeutic factors for a disease of increasing clinical significance.
    Mosquera C; Koutlas NJ; Fitzgerald TL
    Eur J Surg Oncol; 2016 Oct; 42(10):1471-7. PubMed ID: 27528467
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Does surgery provide a survival advantage in non-disseminated poorly differentiated gastroenteropancreatic neuroendocrine neoplasms?
    Thornblade LW; Warner SG; Melstrom L; Ituarte PHG; Chang S; Li D; Fong Y; Singh G
    Surgery; 2021 Jun; 169(6):1417-1423. PubMed ID: 33637345
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical analysis of gastroenteropancreatic neuroendocrine tumor with liver metastasis, compared with primary hepatic neuroendocrine tumor.
    Shen YH; Chen S; Zhang WT; Ji Y; Yu L; Sun HC; Qiu SJ; Ren N; Zhou J
    J Cancer Res Ther; 2014 Dec; 10 Suppl():276-80. PubMed ID: 25693935
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic factors and long-term outcome of pancreatic neuroendocrine neoplasms: Ki-67 index shows a greater impact on survival than disease stage. The large experience of the Spanish National Tumor Registry (RGETNE).
    Martin-Perez E; Capdevila J; Castellano D; Jimenez-Fonseca P; Salazar R; Beguiristain-Gomez A; Alonso-Orduña V; Martinez Del Prado P; Villabona-Artero C; Diaz-Perez JA; Monleon A; Marazuela M; Pachon V; Sastre-Valera J; Sevilla I; Castaño A; Garcia-Carbonero R
    Neuroendocrinology; 2013; 98(2):156-68. PubMed ID: 23988576
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic factors and survival in endocrine tumor patients: comparison between gastrointestinal and pancreatic localization.
    Panzuto F; Nasoni S; Falconi M; Corleto VD; Capurso G; Cassetta S; Di Fonzo M; Tornatore V; Milione M; Angeletti S; Cattaruzza MS; Ziparo V; Bordi C; Pederzoli P; Delle Fave G
    Endocr Relat Cancer; 2005 Dec; 12(4):1083-92. PubMed ID: 16322345
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Surgical treatment of gastrointestinal neuroendocrine tumors.
    Fendrich V; Bartsch DK
    Langenbecks Arch Surg; 2011 Mar; 396(3):299-311. PubMed ID: 21279821
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The epidemiology of gastroenteropancreatic neuroendocrine tumors.
    Lawrence B; Gustafsson BI; Chan A; Svejda B; Kidd M; Modlin IM
    Endocrinol Metab Clin North Am; 2011 Mar; 40(1):1-18, vii. PubMed ID: 21349409
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Survival and clinical outcome of patients with neuroendocrine tumors of the gastroenteropancreatic tract in a german referral center.
    Pape UF; Böhmig M; Berndt U; Tiling N; Wiedenmann B; Plöckinger U
    Ann N Y Acad Sci; 2004 Apr; 1014():222-33. PubMed ID: 15153439
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic factors of long-term outcome in gastroenteropancreatic neuroendocrine tumours.
    Pape UF; Berndt U; Müller-Nordhorn J; Böhmig M; Roll S; Koch M; Willich SN; Wiedenmann B
    Endocr Relat Cancer; 2008 Dec; 15(4):1083-97. PubMed ID: 18603570
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Parathyroid hormone-related peptide (PTHrP) secretion by gastroenteropancreatic neuroendocrine tumors (GEP-NETs): clinical features, diagnosis, management, and follow-up.
    Kamp K; Feelders RA; van Adrichem RC; de Rijke YB; van Nederveen FH; Kwekkeboom DJ; de Herder WW
    J Clin Endocrinol Metab; 2014 Sep; 99(9):3060-9. PubMed ID: 24905065
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Small intestinal neuroendocrine tumors: prognostic factors and survival.
    Bergestuen DS; Aabakken L; Holm K; Vatn M; Thiis-Evensen E
    Scand J Gastroenterol; 2009; 44(9):1084-91. PubMed ID: 19572232
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pancreatic neuroendocrine tumor: A multivariate analysis of factors influencing survival.
    Birnbaum DJ; Turrini O; Ewald J; Barbier L; Autret A; Hardwigsen J; Brunet C; Moutardier V; Le Treut YP; Delpero JR
    Eur J Surg Oncol; 2014 Nov; 40(11):1564-71. PubMed ID: 25086992
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.